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ABSTRACT: Intra‐synovial tendon injuries are a common orthopedic problem with limited treatment options. The synovium is a spe-
cialized connective tissue forming the inner encapsulating lining of diarthrodial joints and intra‐synovial tendons. It contains multi-
potent mesenchymal stromal cells that render it a viable source of progenitors for tendon repair. This study evaluated the effects of
autologous implantation of cells derived from normal synovium (synovial membrane cells [SMCs]) in augmenting repair in an ovine
model of intra‐synovial tendon injury. For this purpose, synovial biopsies were taken from the right digital flexor tendon sheath following
creation of a defect to the lateral deep digital flexor tendon. Mononuclear cells were isolated by partial enzymatic digestion and assessed
for MSC characteristics. Cell tracking and tendon repair were assessed by implanting 5 × 106 cells into the digital flexor tendon sheath
under ultrasound guidance with the effects evaluated using magnetic resonance imaging and histopathology. Synovial biopsies yielded an
average 4.0 × 105± 2.7 × 105 SMCs that exhibited a fibroblastic morphology, variable osteogenic, and adipogenic responses but were
ubiquitously strongly chondrogenic. SMCs displayed high expression of CD29 with CD271NEGATIVE and MHC‐IILOW cell‐surface marker
profiles, and variable expression of CD73, CD90, CD105, CD166, and MHC‐I. Implanted SMCs demonstrated engraftment within the
synovium, though a lack of repair of the tendon lesion over 24 weeks was observed. We conclude healthy synovium is a viable source of
multipotent cells, but that the heterogeneity of synovium underlies the variability between different SMC populations, which while
capable of engraftment and persistence within the synovium exhibit limited capacity of influencing tendon repair. © 2019 The Authors.
Journal of Orthopaedic Research® published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res
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Mesenchymal stem cells (MSCs) have garnered much
scientific interest due to their therapeutic potential in
regenerative medicine and tissue engineering. While
lacking a definitive identity, MSCs are widely acknowl-
edged to exhibit (i) tissue culture plastic adherence; (ii)
spindle‐shaped fibroblastic morphology; (iii) the ability to
form single cell‐derived colonies; (iv) high proliferative
rate; (v) potential for osteogenic, adipogenic, and chon-
drogenic lineage specification; and (vi) the expression of
specific cell surface epitopes.1,2 These defining criteria
have been further extended to include specific gene ex-
pression profiles conferring MSCs with phenotypic mul-
tipotency,3 as well as the production of paracrinal
immunomodulatory trophic factors.4,5 While MSCs have
been isolated from different tissues including synovium,
bone marrow, and adipose tissue remain the
predominantly common sources due to ease of tissue
sampling and isolation of cells from these tissues.2
The synovium is a specialized connective tissue that
covers exposed soft tissues within diarthrodial joints,
tendon sheaths, and bursae.6 It is generally composed
of two layers; a continuous layer overlying tissues
composed of one or two sheets of fibroblastic and mac-
rophage‐like synoviocytes called the intima, and an
underlying collagenous extracellular matrix containing
fibroblastic synoviocytes with blood and lymphatic
vessels called the sub‐intima.2,6 Additionally, the
synovium has been shown to contain multipotent MSCs
with characteristics similar to bone marrow MSCs,7,8
but reportedly with a superior chondrogenic potential,9
and capable of engrafting from the synovium into
tendon matrices in an ex vivo model.10
Intra‐synovial tendinopathies, such as rotator cuff
tears of the shoulder, which are frequently associated with
rupture through the overlying synovial capsule and
therefore exposed to synovial fluid, pose a significant
socio‐economic burden complicated further by limited ef-
fective treatment options. Frequently injury results in
“failed healing” where the tendon integrity has not been
restored. On the basis of encouraging outcomes with the
use of bone marrow MSCs for the treatment of extra‐
synovial naturally occurring tendinopathies in a large
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animal model,11,12 we assessed the reparative efficacy of
bone marrow MSC implantations on repairing intra‐
synovial tendon lesions using an ovine large animal model
that mimics naturally occurring intra‐synovial tendon
disease in humans and horses more accurately than extra‐
synovial tendon locations in small animal models; in-
cluding similar (compressive) biomechanical environment,
an intra‐synovial location, and failure to heal with per-
sistent pain. We hypothesized that implanted cells could
either seal the defect from the synovial environment and/
or participate in regenerative tissue repair. However, au-
tologous bone marrow MSC implantation does not aug-
ment intra‐synovial tendon repair where these cells only
engraft and persist within synovial tissue.13
It is not clear if bone marrow‐derived MSCs could
replace the functional or reparative capacities of native
tissue‐specific MSCs,2 and so this study evaluated the
efficacy of synovial MSCs in augmenting tendon repair
in an ovine model of intra‐synovial tendinopathy. SMCs
carry an advantage, in that they are easily retrievable
from the tendon sheath synovium for use in homologous
fashion (reimplantation into same location from where
originally retrieved). Therefore, we hypothesized that
tissue specificity of synovial MSCs with the intra‐syno-
vial micro‐environment would enable an improved
healing response compared with the ineffectiveness of
bone marrow MSCs.13
MATERIALS AND METHODS
Animal Study
The study was carried out under Home Office (UK) licence
(PPL 70/6964) with approval from the Ethics and Welfare
Committee of the Royal Veterinary College. A total of 26
healthy adult (3–5 years of age) female English mule sheep
were used. Four animals were used to assess the distribution
of iron nano‐particle‐labeled cells at 1 (n = 2) and 2 (n = 2)
weeks post‐implantation. An additional 22 were used to as-
sess the effects of unlabeled cells on tendon repair after 4
(n = 6), 12 (n = 8), and 24 (n = 8) weeks post‐implantation. The
4‐week time point used fewer animals because it was not
anticipated to observe healing this early but rather to be able
to assess other effects of the implanted cells.
Tendon Injury Model
Establishing the injury model and evaluation comprised three
stages: (i) formation of a surgical lesion in the deep digital flexor
tendon (DDFT), (ii) intra‐synovial implantation of cells 2 weeks
post‐surgery, and (iii) euthanasia of animals for gross evaluation
and histological examination at 4, 12, and 24 weeks post‐im-
plantation. For cell tracking experiments, forelimbs were as-
sessed by magnetic resonance imaging (MRI), gross evaluation,
and histological examination at 1 and 2 weeks post‐implantation.
The surgical procedure has been detailed previously.13
Briefly, a linear 5mm long by 2mm deep defect was created in
the lateral DDFT using a disposable triangle knife (ECTRA II;
Smith and Nephew, UK) within the digital sheath immedi-
ately proximal to the metacarpophalangeal joint of the right
forelimb by tenoscopy under general anesthesia. Simulta-
neously a biopsy was taken from the synovium adjacent to the
tendon bifurcation proximal to the site of the lesion using
basket forceps (Fig. 1A–C). Surgical portals were closed with
single simple interrupted sutures of 2‐0 monofilament nylon
and covered in a sterile non‐adherent dressing and bandage.
SMC Implantation
Distal limb circumference above and below the meta-
carpophalangeal joint was measured to assess local in-
flammation. The right limb was prepared aseptically and a 23G
arterial catheter introduced into the lateral compartment of the
proximal tendon sheath under ultrasound guidance, positioned
immediately deep to the flexor tendons and the stylet withdrawn
before 5 × 106 autologous SMCs (passage 2) in 1ml of phosphate‐
buffered saline (PBS) were injected into the sheath. Accurate
placement was identified by the presence of echogenic air bub-
bles present inside the sheath cavity post‐injection. The control
group has been previously reported, which showed no healing for
vehicle‐only (PBS without cells) injected into this sheep tendon
injury model.13
Sheep received two fentanyl patches (75 μg/h; Durogesic,
Aperio Technologies, Vista, CA) 12 h prior to surgery followed
by a second pair 60 h post‐surgery and 0.6mg buprenorphine
(Vetergesic) 72 h later. The sheep were individually housed for
1 week and then group housed with free exercise. Lameness
was assessed subjectively daily.
Euthanasia and Post‐Mortem Analysis
Sheep were euthanized using an overdose of 20% pento-
barbital (0.7mg/kg, mean volume of 40ml/animal). Forelimb
circumference below and above the metacarpophalangeal joint
was remeasured before disarticulation at the carpus for MRI
or dissection for gross and histological analysis.
Dissection and Histology
The digital flexor tendon complex was dissected out as previously
described.13 The DDFT was separated from the superficial digital
flexor tendon (SDFT) and the tissues were divided into 12 seg-
ments (Fig. 1D and E and accompanying table). Paraformalde-
hyde fixed segments were paraffin‐embedded to cut transverse
sections using N35HR blades (Feather) at 8 μm thickness for
hematoxylin and eosin (H&E) or Prussian Blue staining. Digital
whole slide images of tissue sections were generated (Hama-
matsu NanoZoomer s60 or a Leica SCB 400F, Hamamatsu
Photonics, Hamamatsu, Japan) and analyzed with Pathology
Slide Viewing Software NDP View version 2.0 (Hamamatsu) or
Aperio ImageScope version 12.1.0.5029 (Aperio Technologies).
MRI of Sheep Forelimbs
MRI was used to track MION‐labeled cells. Isolated forelimbs
were scanned from the distal aspect of the digits to the mid
metacarpal region with a 1.5 T MR scanner (Philips Intera 1.5 T
Pulsar System; Philips Medical Systems, Guildford, UK). Im-
ages were acquired in the transverse plane with a 61 × 61mm
field of view, 0.55mm slice thickness, and 0.51 × 0.51 × 0.55mm
voxel size. Gradient echo sequences (Flip angle 15°, TR= 30ms)
were chosen over turbo spin echo sequences in order to max-
imize sensitivity to the susceptibility artifact generated by
MION particles, resulting in signal void. In order to differentiate
the hypointense signal generated by MION particles from other
causes of signal void, such as scar tissue (or other fibrous tissue
such as tendons), a dual echo technique (short TE= 7.2ms and
long TE2= 17.4ms) was used. This provided spatially matching
image series, in which the susceptibility artifact associated with
MION would increase in size in the long TE images when
compared with the short TE images, while the size of other
causes of signal void would not be affected.
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Cell Culture
Synovial membrane biopsies were held in 5ml of RPMI‐1640
(Sigma‐Aldrich, Gillingham, UK) in 50ml tubes (Falcon; Fisher
Scientific, Loughborough, UK) on ice during transport to an
aseptic environment. Biopsies were transferred to a 10 cm petri
dish (Nunc) and minced to smaller pieces using a sterile scalpel
(Swann Morton, Sheffield, UK) before mild digestion for 12 h in
growth medium supplemented with 1mg/ml collagenase type IV
(Worthington, UK; cat # 4188) and 1mg/ml of Dispase (Gibco,
Fisher Scientific, Loughborough, UK) in humidified conditions
(5% CO2, 37°C). Growth medium comprised alpha‐MEM (Gibco)
supplemented with 10% fetal bovine serum (Gibco) and 1% an-
tibiotics (Gibco). The resulting slurry was strained through a
40 µm nylon mesh (BD Biosciences, Wokingham, UK) to exclude
undigested tissue and isolated cells pelleted by centrifugation at
400g for 7min before re‐suspending in 5ml of growth medium
for a trypan blue haemocytometer count. Isolated synovial
membrane cells (SMCs) were then seeded in a 75 cm2 tissue
cultures flasks (Nunc) in 15ml of growth medium and cultured
in humidified conditions. Culture medium was changed after
24 h to remove debris and non‐adherent cells and thereafter
after every 48 h within the initial 7 days of culture. Near con-
fluent adherent cells were detached with 0.25% trypsin‐ethyl-
enediaminetetraacetic acid (EDTA) (Gibco) and re‐seeded at a
density of 1,000 cells/cm2 in 75 cm2 tissue culture flasks (Nunc)
to expand to 5 million cells in 2 weeks. Population doubling was
determined with the formula logNF−logNo)/0.301 whereNF was
the final cell number and No was the original number of cells
cultured for the specified duration.
Labeling of Cells
Adherent SMCs were labeled with (Molday ION (MION) Rhod-
amine‐B, BioPal, Worcester, MA) conjugated superparamagnetic
iron oxide nano‐particles according to the manufacture’s guide-
lines (BioPal, Worcester, MA). Briefly, growth medium of cultures
at 70–80% confluence was supplemented with MIONs to a final
concentration of 25 µg/ml and incubated for 2 h. Labeling was
compared with supplementation of protamine sulfate (Sigma‐
Aldrich) to a final concentration of 100 µg/ml to enhance MION
labeling. Cultures were washed twice with PBS to remove free
MIONs and detached as described above.
Colony Forming Unit Assay
Colony forming unit analysis was performed by seeding
100 cells suspended in 3ml of growth medium on 6 cm tissue
culture petri‐dishes (Nunc). Cultures were maintained in hu-
midified conditions with bi‐weekly medium changes for
14 days and stained by 0.5% (m/v) crystal violet (Sigma‐Aldrich)
in absolute methanol (Sigma‐Aldrich). Samples were scanned to
a gray‐scale image on a flatbed scanner (Epson, Hemel Hemp-
stead, UK) at 1,200 dpi and colonies counted with (ImageJ,
U. S. National Institutes of Health, Bethesda, MD).
Confocal Microscopy
Confocal microscopy was used to visualize MION uptake by
seeding 5 × 104 labeled cells on treated chamber slides (Nunc,
Thermo Fisher Scientific, UK) for 24 h and to additionally
assess persistence of label in cells after 7 days of culture.
Samples were fixed in 2% paraformaldehyde (Fisher Scien-
tific) in PBS (Gibco) and overlaid with DAPI supplemented
mounting medium (Vector Laboratories, Peterborough, UK)
for confocal microscopy (Leica 710 confocal microscope; Leica,
Milton Keynes, UK).
Trilineage Differentiation
Random cell samples (n = 7) were selected for an assessment
of tri‐lineage differentiation and evaluated as previously de-
scribed for bone marrow‐derived MSCs.13
Flow cytometery
SMCs (n = 3–9, passage 2 or 3) were immunophenotypically
evaluated for the expression of cell surface markers with flow
cytometery according to Khan et al.14 Details of the antibodies
used have been detailed in Khan et al. except for CD34 (clone
QBEND/10, mouse antibody with reactivity to human, cat. no.
SFL547PE; Bio‐Rad, Langford, UK). Briefly, near confluent
MSC populations, expanded for 7 days at an initial cell seeding
density of 1,000 cells/cm2, which were detached with a 3:2 (v/v)
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Figure 1. Ovine intra‐synovial digital flexor tendons. (A) Arthroscopic image of the extraction of a synovium biopsy from the digital
flexor tendon sheath. (B) Dorsal view of the digital flexor tendon complex after dissection from the forelimb showing the deep digital
flexor tendon (DDFT) overlaid by the superficial digital flexor tendon (SDFT). Arrow indicates the area of biopsy extraction. Arrowheads
indicate lesion in the lateral deep digital flexor tendon. (C) Dorsal view of the deep digital flexor tendon with white arrowheads pointing
towards the lesion. Delineations represent tissue segmentations of the DDFT and SDFT for histology that are elaborated in the
accompanying table. [Color figure can be viewed at wileyonlinelibrary.com]
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combination of Accutase (StemPro; Life Technologies, Paisley,
UK) and EDTA (Gibco, Life Technologies, Paisley, UK) and fixed
in 4% paraformaldehyde in PBS for 30min at room temper-
ature. The cells were washed and re‐suspended at 1 × 106 cells/
ml in staining buffer, comprising PBS supplemented with 10%
FBS, sheep serum, goat serum (giving a final concentration of
30% serum) with 100mg/ml bovine serum albumin (all from
Sigma‐Aldrich, Dorset, UK). A 100 µl of suspension containing
1 × 105 cells was plated per well of a 96‐well plate (Nunc
Thermo Scientific, Paisley, UK) for each antibody and incubated
for 2 h at room temperature and protected from light. The cells
were then washed and re‐suspended in 1ml of PBS in FACS
tubes (12mm x 75mm, Thermo Fischer, Paisley, UK) for anal-
ysis on a FACS Calibur (BD Biosciences) with a threshold of a
minimum of 2.5 × 104 events. The cells were gated based on
homogeneity in forward and side scatter properties with fluo-
rescence intensity changes assessed against non‐labeled cells
using FlowJo (version 10).
Statistics
Quantitative data was collated in (GraphPad Prism version 7,
San Diego, CA) and expressed as the mean± SD. In vitro
analyses of cellular characteristics involved different
technical replicates depending on the assay outcomes and are
stated in descriptions of the methods used. Trilineage differ-
entiation was performed in three technical replicates for each
SMC population. Flow cytometric analyses were performed in
tandem with each SMC population in the serial analysis iso-
lated from a different sheep. Histological whole slide imaging
scans were categorically assessed for repair.
RESULTS
Effects of Surgical Lesion and SM Biopsy in Sheep
The tendon defect was well‐tolerated with animals not
exhibiting lameness or any significant change in body
mass during the experiment. There was no significant
increase in limb swelling after surgical intervention or
extraction of SM biopsies.
Characteristics of SMCs
SM biopsies had an average weight of 97.0± 92.8mg
(n=20) (Fig. 2A) yielding a mean 4.0 × 105± 3.7 × 105 cells
(n=20) (Fig. 2A) per biopsy. These cells adhered to tissue
culture with a spindle‐like fibroblastic morphology
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Figure 2. Characteristics of plastic adherent ovine synovial membrane cells. (A–C) XY scatter plot of the number of cells isolated
compared with weight of synovium biopsy (A), population doublings over 7 days compared with number of isolated cells and population
doubling time compared with population doublings over 7 days. Note that the biopsies occurring on the axis yielded 0.1, 0.5, and 0.2mg of
tissue. (D) Box‐whisker plot of minimum to maximum readings with median of clonogenic efficiency of cell lines (n = 3). (E) Scan of 6 cm
petri‐dish stained for colonies with crystal violet. (F) Phase contrast microscopic image (×20 objective) of cells. (G–I) Confocal micro-
graphs at ×40 magnification indicating cells without MION label (G), cells containing with MION label (H), cells containing MION label
in presence of protamine sulfate. (J) Fluorescent micrographs at low magnification showing MION retention after 7 days of culture.
[Color figure can be viewed at wileyonlinelibrary.com]
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exhibiting 2.03± 1.11 (n=19) population doublings in the
initial 7 days (passage 0–1) with a mean population dou-
bling time of 106.8± 99.2 h (n=19) (Fig. 2B–C). The
(CFU, Colony Forming Unit) efficiency was determined to
be 12.0± 7.0% (n=12) in passage 1, which after re‐plating
had increased to 19.6± 6.2% (n=5) in passage 2 without
any significant change occurring in passage 3 (data not
shown). SMCs labeled for cell tracking experiments dem-
onstrated successful uptake of MIONs, which was not
enhanced by the addition of protamine sulfate (Fig. 2G–I).
MION label persisted in cells cultured for 7 days (Fig. 2J)
without affecting cellular proliferation (data not shown).
Tri‐Lineage Differentiation
SMCs exhibited variable osteogenic and adipogenic dif-
ferentiation but were ubiquitously strongly chondrogenic.
Five out of seven cell lines showed moderate Alizarin Red
S staining after culture in osteogenic differentiation me-
dium for 14 days (Fig. 3A–G). Only 3/7 of the SMCs
displayed strong Oil Red O positive staining of cytoplasmic
lipid vacuoles (Fig. 3H–N). All cell lines stained positive for
glycosaminoglycan (GAG)‐related Alcian Blue and Sa-
franin O staining (Fig. 4A–G). MION labeling had an
inhibitory effect on osteogenic and adipogenic differ-
entiation (data not shown) and resulted in reduced GAG
staining in 2/3 cell lines tested for chondrogenic differ-
entiation (Fig. 4E–G).
Flow Cytometry of Cell Surface Markers
SMCs were highly variable for the expression of MSC‐
related cell‐surface markers (Fig. 5). The fibroblastic
markers CD29 (99.9± 0.0%) and CD44 (98.7± 2.8%) were
ubiquitously detected in all cell lines tested. However, the
expression of CD73 (65.4± 28.1%), CD90 (41.8± 35.4%),
CD166 (45.0± 30.3%), and MHC‐I (72.5± 22.8%) were
inconsistent between the different cell lines, which also
exhibited low numbers of CD105 (15.3± 12.8%) positive
cells. A dual stain experiment (n=3) demonstrated a
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Figure 3. Osteogenic and adipogenic differentiation of ovine synovial membrane cells (SMCs). (A–G) Microscopic images of SMC lines
(n = 7) after 14 days of incubation in osteogenic inductive medium, indicating variability of Alizarin Red S stain retention. (H–N) Images
of Oil Red O staining of SMCs cultured in adipogenic differentiation medium for 14 days, indicating presence (H–J) and absence of
staining (K–N). [Color figure can be viewed at wileyonlinelibrary.com]
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differential expression and co‐localization of CD166 with
CD29 (68.8± 7.3%) and CD44 (58.5± 25.1%) in three SMC
populations (Fig. 6). All cell lines tested negative for the
expression of CD271 (0.2± 0.1%) and contained low levels
of cells positive for monocyte markers MHC‐II (6.8± 6.3%)
and CD34 (0.3± 0.3%) but had elevated levels of CD45
(39.4± 38.6%), possibly indicative of leukocytic con-
tamination.
Magnetic Resonance Imaging for Tracking MION‐Labeled
Cells
MRI indicated the presence of multiple susceptibility ar-
tifacts comparable with MION‐labeled cells in the lateral
and medial aspects of the tendon sheath. The lesion was
not clearly identified in these scans (Fig. 7). Some of these
signals were identified in the surgical and instrument
portals (Fig. 7C) while other signals seemed restricted to
the digital flexor tendon sheath (Fig. 7D). MRI could not
differentiate the hypointense signal of the MION‐labeled
SMCs from the hypointense tendon signal and was in-
sensitive to single or small groups of cells for quantitative
assessment on cell distribution.
Gross Parameters of the Tendon Synovial Sheath and
Lesion
There was minimal inflammation of the digital flexor
tendon sheath with only 2/8 sheep at 24 weeks ex-
hibiting distension. Fluid was visible in 2/6 sheep at
4 weeks, 1/8 sheep at 12 weeks, and 2/8 sheep at
24 weeks. The lesion was macroscopically visible in all
sheep at post‐mortem. The lesion in 1/6 sheep at 4 week
and 5/8 sheep at 24 weeks appeared to be closed but
was easily disrupted following gentle manipulation.
Prolapsed fibers were visible in 2/6, 2/8, and 4/8 at 4,
12, and 24 weeks, respectively. There were no adhe-
sions observed in any of the sheep treated with SMCs.
Histological Assessment of the Effects of Cell Implantation
Histological examination of sheep treated with MION‐
labeled SMCs indicated prussian blue positive cells
within the palmar synovial tissue (segment J in Fig. 1E)
on the palmar surface of the SDFT (Fig. 8A–F) and the
dorsal synovial tissue (segment K in Fig. 1D), which was
the opposing synovial tissue to the DDFT. However, la-
beled cells were neither within the synovial covering of
the DDFT nor the tendon lesion (Fig. 8G). Prussian blue
positive cells were detected as non‐homogeneous clusters
engrafted within the synovium and distinct from iron
associated with cells within the blood vessels (Fig. 8B–F).
Histological evaluation of transverse sections of the deep
digital flexor tendon in sheep treated with non‐labeled
MSCs showed the persistence of the tendon lesion in all
groups at 4, 12, and 24 weeks (Fig. 8H–J). These included
those tendons that appeared closed on gross examination,
indicating an absence of tendon healing.
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Figure 4. Chondrogenic differentiation of ovine synovial membrane cells (SMCs). Whole slide images of chondrogenic cell pellets after
staining with hematoxylin and eosin (H&E), Alcian Blue, Safranin O, and Prussian blue. [Color figure can be viewed at wileyonlineli-
brary.com]
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DISCUSSION
In spite of the closer relationship to injured intra‐
synovial tendon tissue (synovial cells line intact ten-
dons within a tendon sheath), this study demonstrated
that SMCs, like bone marrow‐derived MSCs, are in-
capable of engrafting into the tendon defect and do not
enhance healing of an intra‐synovial tendon injury in
this sheep model of tendinopathy, although they are
able to engraft into synovium. No adhesions were found
after implantation of SMCs, which is a common con-
sequence of intra‐synovial tendon healing in some lo-
cations (e.g., the hand). One limitation of this study was
the absence of quantitative assessment of tendon
function, such as mechanical properties. However, this
model creates a longitudinal split in the tendon, which
is unlikely to significantly influence the tendon’s me-
chanical properties. Furthermore, the goal was to as-
sess the potential of SMCs to either seal the defect from
the synovial environment and/or participate in re-
generative repair. A major concern with tears commu-
nicating with the synovial environment is persistent
inflammation due to the shedding of tendon ex-
tracellular matrix components into the synovial cavity.
Hence, the ability of SMCs to engraft and seal the de-
fect would have a major therapeutic benefit.
The SMCs recovered from normal tendon sheath
synovium were found to be a heterogeneous population
of cells exhibiting differences in proliferation, clonoge-
nicity, multipotentiality, and cell‐surface marker ex-
pression. While displaying an overall spindle‐like
fibroblastic morphology similar to bone marrow‐derived
MSCs, SMCs yielded substantially lower number of
CFUs compared with percentages commonly reported
for bone marrow MSCs.13,15 The highly variable pop-
ulation doubling times of SMCs also contrasted with
that reported for bone marrow MSCs (106.8± 99.2 and
32.29± 1.72 h, respectively).13 Osteogenic and adipo-
genic responses also varied but appeared not be related
to tissue biopsy cell yield or cell proliferation data.
Chondrogenic differentiation was ubiquitously strong
as shown previously for synovium‐derived cells,9 and
was irrespective of biopsy size, initial number of iso-
lated cells, or capacity of osteogenic/adipogenic differ-
entiation. These observations infer that the isolated
SMC populations had a propensity toward a chondro-
genic phenotype, which has also been reported for ovine
MSCs recovered from synovial fluid.16
Flow cytometry revealed a highly variable cell‐sur-
face marker profile between SMCs isolated from dif-
ferent biopsies. While the abundance of multipotent
cells within healthy synovium is reportedly lower than
in pathological synovium such as osteoarthritis, it may
also differ between sub‐anatomical locations as dem-
onstrated for inflammed synovium from osteoarthritic
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Figure 5. Immunophenotypic analysis of ovine synovial membrane cells (SMCs).
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knee joints.17,18 It is likely that the digital synovium
has similar complex sub‐tissues that contribute to the
observed heterogeneity. The impact on SMC phenotypic
characteristics from their synovial, perivascular, or fi-
brous connective origin, as well as the inflammatory
state of the synovium from which they were derived,
may significantly influence the outcomes of re-
generative approaches for tendon repair.19 A relevant
example is the absence of expression of cell‐surface
marker CD271, a low affinity neural growth factor re-
ceptor reported to be a marker of multipotent cells;
while largely absent in normal healthy synovium cells
it is upregulated in pathologic inflammed synovial
tissue.2,20,21 Similarly, SMC characteristics appear
profoundly influenced by joint type with knee‐derived
tissue deemed a preferable source for multipotent cells
than the hip joint due to the stronger osteogenic and
adipogenic differentiation responses of cells,22 which
may further vary for synovium located in tendon
sheaths.
While cell‐surface marker expression showed consistent
high expression for two robust MSC markers, CD29 and
CD44, there was a wide range in expression for CD73,
CD90, CD166, and MHC‐I. CD105 was expressed at lower
levels compared with our observations with ovine bone
marrow MSCs,13,14 and an absence of CD271 expression,
which is consistent with reports in normal human joint
synovium.21,23,24 While the hematopoietic marker CD34
was absent, there was variable expression of CD45 and
MHC‐II, indicating potential inclusion of leukocytic cells
from perivascular tissue. However, these profiles are not
dissimilar to recent studies of synovial MSCs derived from
inflammed human knee joints.18,21–23,25–27 Hagmann
et al.25 reported differences between donor‐typed bone
marrow and synovial MSCs with the latter uniformly ex-
hibiting trilineage differentiation and strongly positive for
CD73, CD90, CD105, and MHC‐I although small levels of
CD34 and CD45 positive cells were also detected. A com-
parable yield of cells from synovium have been isolated
from pathological knee and hip joints exhibiting a “mixed”
cell‐surface marker profile similar to this study.22 Fur-
thermore, a similar cell‐surface marker expression profile
for synovium‐derived trilineage positive cells has been
reported in this study, though the authors have
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Figure 6. Flow cytometric analysis of dual staining assessing the co‐localization of CD166 with CD29 and CD44 in three synovial
membrane cell (SMC) lines. Each of these cell lines displayed different percentages of CD166 co‐localization with CD29 and CD44 in
addition to the variable expression of the marker between CD166 positive cells. [Color figure can be viewed at wileyonlinelibrary.com]
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interpreted CD166 as a possible discriminating factor be-
tween multipotent and fibroblastic cells.26 In contrast,
assessing the ameliorative effects of synovial MSCs in an
osteoarthritic mouse model, synovial MSCs were reported
to be highly positive for CD73, CD90, and CD105.27 The
lack of CD105 and CD271 with moderate CD73 positive
cells was reported for the surface and stromal synovia
from human arthritic joints.18 These findings correspond
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Figure 7. Magnetic resonance imaging (MRI) scans of distal forelimbs implanted with MION‐labeled synovial membrane cells (SMCs).
Distal forelimb MRI scans along the (A) dorsal and (B) para‐sagittal planes, in which red indicates the metacarpals, blue indicates
proximal phalanges, and yellow indicates proximal sesamoid bones. White arrow head indicates instrument portal and orange indicates
the surgical incision, tendon lesion, and injection site. (C) Proton density (PD) and T2‐weighted (T2) transverse images at the proximal
aspect of the tendon sheath, just distal to the bifurcation of the DDFTs. Multiple susceptibility artifacts comparable with MION are
identified, and as expected are slightly more extensive on T2 than PD. This includes the instrument portal (orange), a moderate size area
in the lateral (red), and medial (blue) aspect of the tendon sheath. (D) PD (left) and T2 (right) slightly distal to the bifurcation of the deep
digital flexor tendon (DDFT) (first row) and at the apex of the proximal sesamoid bones (second row). MIONs identified along both the
lateral (red) and medial (blue) aspect of the tendon sheath. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 8. Histological assessment of ovine intra‐synovial digital flexor tendons. (A) Transverse section of synovial tissue overlying
superficial digital flexor tendon (SDFT) at the tendon bifurcation site (segment J). (B–F) High magnification images of Prussian Blue
stained cells (arrowheads) within the synovial tissue. (G) Transverse section of deep digital flexor tendon (DDFT) showing lesion at 2
weeks post‐implantation but absence of Prussian Blue staining. (H–J) Transverse sections of DDFTs after 4 (H), 12 (I), and 24 (J) weeks
post‐implantation, indicating persistence of surgical lesion. [Color figure can be viewed at wileyonlinelibrary.com]
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to the SMC heterogeneity seen in this study supporting
our view that the variability is likely due to the inclusion
of stromal and perivascular synovial tissue in biopsies. It
may be possible to reduce this heterogeneity by applying
retrieval methods such as those recently described for re-
trieving minimally manipulated SMCs from joints with
greater cellular homogeneity.28 It remains to be estab-
lished whether such cell populations are more amenable to
effect tendon repair although our observations suggest
that none of the subsets are capable of engrafting in the
tendon defect.
The results of this study indicated an inverse cor-
relation between the number of SMCs isolated and
tissue weight, and a trend that corresponded with
population doubling and population doubling time
suggesting that smaller biopsies likely yielded a greater
abundance of proliferative spindle‐shaped SMCs. Al-
though we did not extend the population doubling ex-
periments until exhaustion of proliferative capacity, a
small decrease in CFU ability upon re‐plating SMCs for
the second passage was observed.
The ovine SMCs in this study displayed engraftment
and migration within the synovium as a result of ho-
mologous implantation, appearing as homogeneously
distributed clusters within synovial tissue though
failing to adhere the intact tendon surface or the lesion,
similar to bone marrow‐derived MSCs.13 This selective
engraftment of cells to the synovium, although in small
numbers as previously shown for MSCs,13 and lack
thereof to the tendon suggests that synovium is the
preferred niche for these cells. It therefore remains to
be established whether SMCs or other multipotent cells
can be applied successfully for tendon repair for in-
juries that occur within the synovium sheath. We pro-
pose the absence of healing within this compartment, in
addition to the innate inability for synovially located
tendons to repair, is due to the infiltration of the
synovial fluid into the injured tendon matrix, which we
have previously shown to be toxic to both MSCs and
tendon fibroblasts,29 and that intra‐synovially injected
cells are not able to seal the tendon lesion from the
synovial environment because of their lack of adher-
ence to tendon matrix as well as poor adherence to the
tendon surface. Future work elucidating the underlying
mechanism of cellular engraftment and migration
within the synovium could allow the directed homing of
MSCs to tendon repair sites or enhancement of cell
retention such as with scaffolds as described for elec-
trospun nanofiber sutures in a rat model of rotator cuff
ruptures,30 thereby significantly contributing to the
effectiveness of therapeutic strategies for intra‐syno-
vial tendon repair.
CONCLUSION
The healthy synovium in tendon sheaths is a viable
source of multipotent progenitor cells. The abundance
of these cells is variable; however, despite their het-
erogenous nature, SMCs show similar engraftment and
persistence within synovium but not within intact
tendon or tendon lesions. Although the SMC pop-
ulations did not augment tendon healing as assessed in
this study, further understanding of the mechanisms of
engraftment could lead to more successful cellular
therapies for intra‐synovial tendon repair.
AUTHORS’ CONTRIBUTION
The study was conceived by R.K.W.S., A.J.C., J.D., and
A.E.G. R.K.W.S., R.D.G., and G.H. performed the sur-
geries. F.D. and R.L. performed MRI scans. M.R.K. con-
ducted the cell culture work, flow cytometery, and whole
slide imaging. M.R.K. and J.D. performed dissections,
gross histological assessments of tissues, and histological
analyses. M.R.K. wrote the draft of the manuscript and
revised it. R.K.W.S. and J.D. revised the manuscript.
ACKNOWLEDGMENTS
The authors would like to acknowledge the technical as-
sistance provided by the staff of the Biological Services
Unit and the Pathology services for histology of the Royal
Veterinary College. The assigned manuscript approval
number is CSS_02007.
DATA AVAILABILITY
The datasets generated during and/or analyzed during
the current study are available from the corresponding
author on reasonable request.
REFERENCES
1. Dominici M, Le Blanc K, Mueller I, et al. 2006. Minimal cri-
teria for defining multipotent mesenchymal stromal cells. The
International Society for Cellular Therapy position state-
ment. Cytotherapy 8:315–317.
2. de Sousa EB, Casado PL, Neto VM, et al. 2014. Synovial fluid
and synovial membrane mesenchymal stem cells: latest dis-
coveries and therapeutic perspectives. Stem Cell Res Ther
5:1–6.
3. Boeuf S, Richter W. 2010. Chondrogenesis of mesenchymal
stem cells: role of tissue source and inducing factors. Stem
Cell Res Ther 1:31.
4. Caplan AI, Dennis JE. 2006. Mesenchymal stem cells as
trophic mediators. J Cell Biochem 98:1076–1084.
5. Meirelles Lda S, Fontes A, Covas D, et al. 2009. Mechanisms
involved in the therapeutic properties of mesenchymal stem
cells. Cytokine Growth Factor Rev 20:419–427.
6. D. smith M. 2011. The normal synovium. Open Rheumatol J
5:100–106.
7. De Bari C, Dell’accio F, Tylzanowski P, et al. 2001. Multi-
potent mesenchymal stem cells from adult human synovial
membrane. Arthritis Rheum 44:1928–1942.
8. Jones EA, Crawford A, English A, et al. 2008. Synovial fluid
mesenchymal stem cells in health and early osteoarthritis:
detection and functional evaluation at the single‐cell level.
Arthritis Rheum 58:1731–1740.
9. Sakaguchi Y, Sekiya I, Yagishita K, et al. 2005. Comparison of
human stem cells derived from various mesenchymal tissues:
superiority of synovium as a cell source. Arthritis Rheum 52:
2521–2529.
10. Hayashi M, Zhao C, An KN, et al. 2012. Cell migration after
synovium graft interposition at tendon repair site. Hand 7:
374–379.
11. Smith RKW, Werling NJ, Dakin SG, et al. 2013. Beneficial
effects of autologous bone marrow‐derived mesenchymal stem
cells in naturally occurring tendinopathy. PLoS ONE 8:1–14.
JOURNAL OF ORTHOPAEDIC RESEARCH® MONTH 2019
10 KHAN ET AL.
12. Godwin EE, Young NJ, Dudhia J, et al. 2012. Implantation of
bone marrow‐derived mesenchymal stem cells demonstrates
improved outcome in horses with overstrain injury of the
superficial digital flexor tendon. Equine Vet J 44:25–32.
13. Khan MR, Dudhia J, David FH, et al. 2018. Bone marrow
mesenchymal stem cells do not enhance intra‐synovial tendon
healing despite engraftment and homing to niches within the
synovium. Stem Cell Res Ther 9:169.
14. Khan MR, Chandrashekran A, Smith RKW, et al. 2016. Im-
munophenotypic characterization of ovine mesenchymal.
Stem Cells Cytom Part A 89:443–450.
15. Sekiya I, Larson BL, Smith JR, et al. 2002. Expansion of
human adult stem cells from bone marrow stroma: conditions
that maximize the yields of early progenitors and evaluate
their quality. Stem Cells 20:530–541.
16. Burk J, Glauche SM, Brehm W, et al. 2017. Characterisation
and intracellular labelling of mesenchymal stromal cells de-
rived from synovial fluid of horses and sheep. Vet J 222:1–8.
17. Hermida‐Gómez T, Fuentes‐Boquete I, Gimeno‐Longas MJ,
et al. 2011. Quantification of cells expressing mesenchymal
stem cell markers in healthy and osteoarthritic synovial
membranes. J Rheumatol 38:339–349.
18. Mizuno M, Katano H, Mabuchi Y, et al. 2018. Specific markers
and properties of synovial mesenchymal stem cells in the surface,
stromal, and perivascular regions. Stem Cell Res Ther 9:123.
19. De Bari C, Dell’accio F, Vandenabeele F, et al. 2003. Skeletal
muscle repair by adult human mesenchymal stem cells from
synovial membrane. J Cell Biol 160:909–918.
20. De Bari C, Dell’accio F, Karystinou A, et al. 2008. A bio-
marker‐based mathematical model to predict bone‐forming
potency of human synovial and periosteal mesenchymal stem
cells. Arthritis Rheum 58:240–250.
21. Karystinou A, Dell’accio F, Kurth TBA, et al. 2009. Distinct
mesenchymal progenitor cell subsets in the adult human
synovium. Rheumatology 48:1057–1064.
22. Hatakeyama A, Uchida S, Utsunomiya H, et al. 2017. Iso-
lation and characterization of synovial mesenchymal stem
cell derived from hip joints: a comparative analysis with a
matched control knee group. Stem Cells Int 2017:1–13.
23. Van Landuyt KB, Jones EA, McGonagle D, et al. 2010. Flow
cytometric characterization of freshly isolated and culture
expanded human synovial cell populations in patients with
chronic arthritis. Arthritis Res Ther 12:R15.
24. Toyoda E, Sato M, Takahashi T, et al. 2019. Multilineage‐
differentiating stress‐enduring (Muse)‐like cells exist in
synovial tissue. Regen Ther 10:17–26.
25. Hagmann S, Rimmele C, Bucur F, et al. 2016. Mesenchymal
stromal cells from osteoarthritic synovium are a distinct
population compared to their bone‐marrow counterparts re-
garding surface marker distribution and immunomodulation
of allogeneic CD4+ T‐cell cultures. Stem Cells Int 2016:1–17.
26. Fernandes TL, Kimura HA, Pinheiro CCG, et al. 2018.
Human synovial mesenchymal stem cells good manufacturing
practices for articular cartilage regeneration. Tissue Eng Part
C Methods 24:709–716.
27. Yin L, Wu Y, Yang Z, et al. 2018. Microfluidic label‐free se-
lection of mesenchymal stem cell subpopulation during cul-
ture expansion extends the chondrogenic potential in vitro.
Lab Chip 18:878–889.
28. Baboolal TG, Khalil‐Khan A, Theodorides AA, et al. 2018. A novel
arthroscopic technique for intraoperative mobilization of synovial
mesenchymal stem cells. Am J Sports Med 46:3532–3540.
29. Garvican ER, Salavati M, Smith RKW, et al. 2017. Exposure
of a tendon extracellular matrix to synovial fluid triggers
endogenous and engrafted cell death: a mechanism for failed
healing of intrathecal tendon injuries. Connect Tissue Res 58:
438–446.
30. Peach MS, Ramos DM, James R, et al. 2017. Engineered stem
cell niche matrices for rotator cuff tendon regenerative
engineering. PLoS ONE 12:e0174789.
JOURNAL OF ORTHOPAEDIC RESEARCH® MONTH 2019
EFFECTS OF MULTIPOTENT CELLS ON TENDON REPAIR 11
